Retrospective evaluation of COVID-19 incidence during smoking cessation treatment with varenicline

Elif Barış; Gökçen Ömeroğlu Şimşek; Aylin Arici; Mukaddes Gümüştekin; Oğuz Kılınç; Metiner Tosun

Makale detayları

Retrospective evaluation of COVID-19 incidence during smoking cessation treatment with varenicline

Yazarlar:

Elif Barış | Gökçen Ömeroğlu Şimşek | Aylin Arici | Mukaddes Gümüştekin | Oğuz Kılınç | Metiner Tosun

Yayıncı:

Manisa Celal Bayar University

Ana Başlıklar:

Klinik Tıp Bilimleri | Bulaşıcı Hastalıklar

Dergi:

Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi Vol.11 Issue 1, pp.30-35

Belge Tipi:

Makale

Yayın Tarihi:

3/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001314102

pISSN:

2147-9607

Anahtar kelimeler:

Özet:

 Background: Cholinergic anti-inflammatory pathway endogenously controls inflammatory processes through activation of the α7-nicotinic acetylcholine receptor α7nAChR. Varenicline, used in smoking cessation therapy, is a full α7nAChR agonist with anti-inflammatory effects. In this study, the frequency of coronavirus disease COVID-19 was evaluated in patients using varenicline as a smoking cessation treatment. Methods: In this retrospective cross-sectional study, records of the 111 patients admitted to Smoking Cessation Outpatient Clinic of Dokuz Eylul University Faculty of Medicine during the COVID-19 pandemic were evaluated. The development of COVID-19 disease according to the status of the patients being positive for SARS-COV-2 was evaluated comparatively in patients who received varenicline or not. Additionally, the disease symptoms were questioned. Results: SARS-CoV-2 PCR positivity was not detected in any of 38 patients who regularly used varenicline out of 68 patients evaluated. SARS-CoV-2 PCR positivity was detected in 13 43.3 of 30 patients who received other treatments or irregularly used varenicline p0.001. Conclusions: Patients under smoking cessation treatment did not develop COVID-19 during the period of varenicline use compared to non-users suggesting that the medication may have a protective role in the development of COVID-19 which might be further investigated by clinical trials.

 Background: Cholinergic anti-inflammatory pathway endogenously controls inflammatory processes through activation of the α7-nicotinic acetylcholine receptor α7nAChR. Varenicline, used in smoking cessation therapy, is a full α7nAChR agonist with anti-inflammatory effects. In this study, the frequency of coronavirus disease COVID-19 was evaluated in patients using varenicline as a smoking cessation treatment. Methods: In this retrospective cross-sectional study, records of the 111 patients admitted to Smoking Cessation Outpatient Clinic of Dokuz Eylul University Faculty of Medicine during the COVID-19 pandemic were evaluated. The development of COVID-19 disease according to the status of the patients being positive for SARS-COV-2 was evaluated comparatively in patients who received varenicline or not. Additionally, the disease symptoms were questioned. Results: SARS-CoV-2 PCR positivity was not detected in any of 38 patients who regularly used varenicline out of 68 patients evaluated. SARS-CoV-2 PCR positivity was detected in 13 43.3 of 30 patients who received other treatments or irregularly used varenicline p0.001. Conclusions: Patients under smoking cessation treatment did not develop COVID-19 during the period of varenicline use compared to non-users suggesting that the medication may have a protective role in the development of COVID-19 which might be further investigated by clinical trials.

 Background: Cholinergic anti-inflammatory pathway endogenously controls inflammatory processes through activation of the α7-nicotinic acetylcholine receptor α7nAChR. Varenicline, used in smoking cessation therapy, is a full α7nAChR agonist with anti-inflammatory effects. In this study, the frequency of coronavirus disease COVID-19 was evaluated in patients using varenicline as a smoking cessation treatment. Methods: In this retrospective cross-sectional study, records of the 111 patients admitted to Smoking Cessation Outpatient Clinic of Dokuz Eylul University Faculty of Medicine during the COVID-19 pandemic were evaluated. The development of COVID-19 disease according to the status of the patients being positive for SARS-COV-2 was evaluated comparatively in patients who received varenicline or not. Additionally, the disease symptoms were questioned. Results: SARS-CoV-2 PCR positivity was not detected in any of 38 patients who regularly used varenicline out of 68 patients evaluated. SARS-CoV-2 PCR positivity was detected in 13 43.3 of 30 patients who received other treatments or irregularly used varenicline p0.001. Conclusions: Patients under smoking cessation treatment did not develop COVID-19 during the period of varenicline use compared to non-users suggesting that the medication may have a protective role in the development of COVID-19 which might be further investigated by clinical trials.

 Giriş ve Amaç: Kolinerjik anti-inflamatuar yol, α7-nikotinik asetilkolin reseptörünün α7nAChR aktivasyonu ile inflamatuar süreçlerin endojen kontrolünü sağlamaktadır. Sigarayı bırakma tedavisinde kullanılan vareniklin, bir α7nAChRlerine agonist etkisi ile anti-inflamatuvar etkiler ortaya çıkarmaktadır. Bu çalışmada sigara bırakma tedavisi olarak vareniklin kullanan hastalarda koronavirüs hastalığı COVID-19 görülme sıklığı değerlendirilmiştir. Yöntemler: Bu retrospektif kesitsel çalışmada, COVID-19 pandemisi sırasında Dokuz Eylül Üniversitesi Tıp Fakültesi Sigara Bırakma Polikliniğine başvuran 111 hastanın kayıtları değerlendirilmiştir. SARS-COV-2 PCR pozitif olan hastalarda COVID-19 gelişimi ve hastalık belirtileri, vareniklin kullanan ve kullanmayan hastalarda karşılaştırmalı olarak değerlendirilmiştir. Bulgular: Değerlendirilen 68 hastadan düzenli olarak vareniklin kullanan 38 hastada SARS-CoV-2 PCR pozitifliği saptanmamıştır. Sigara bırakma amacıyla farklı tedavileri alan veya düzensiz vareniklin kullanan 30 hastanın 13ünde 43,3 SARS-CoV-2 PCR pozitifliği saptanmıştır p0,001. Sonuç: Sigarayı bırakma tedavisi gören hastalarda, vareniklin kullanmayanlara hastalara kıyasla düzenli vareniklin kullanımı süresince COVID-19 gelişmemesi, bu da ilacın COVID-19 gelişiminde koruyucu bir rolü olabileceğini düşündürmektedir.

Makale detayları

Retrospective evaluation of COVID-19 incidence during smoking cessation treatment with varenicline

Yazarlar:

Elif Barış | Gökçen Ömeroğlu Şimşek | Aylin Arici | Mukaddes Gümüştekin | Oğuz Kılınç | Metiner Tosun

Yayıncı:

Manisa Celal Bayar University

Ana Başlıklar:

Klinik Tıp Bilimleri | Bulaşıcı Hastalıklar

Dergi:

Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi Vol.11 Issue 1, pp.30-35

Belge Tipi:

Makale

Yayın Tarihi:

3/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001314102

pISSN:

2147-9607

COVID-19

SARS-CoV-2

Retrospective Study

Smoking Cessation Therapy

VareniclineCOVID-19

SARS-CoV-2

Retrospektif Araştırma

Sigara Bırakma Tedavisi

Vareniklin

Sayı

Makale detayları

Yazarlar: Elif Barış | Gökçen Ömeroğlu Şimşek | Aylin Arici | Mukaddes Gümüştekin | Oğuz Kılınç | Metiner Tosun

Yayıncı: Manisa Celal Bayar University

Ana Başlıklar: Klinik Tıp Bilimleri | Bulaşıcı Hastalıklar

Dergi: Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi Vol.11 Issue 1, pp.30-35

Belge Tipi: Makale

Yayın Tarihi: 3/2024

Belge Dili: İngilizce

Document ID (Org No.): 2001314102

pISSN: 2147-9607

Sayı

Yazarlar:

Elif Barış | Gökçen Ömeroğlu Şimşek | Aylin Arici | Mukaddes Gümüştekin | Oğuz Kılınç | Metiner Tosun

Yayıncı:

Manisa Celal Bayar University

Ana Başlıklar:

Klinik Tıp Bilimleri | Bulaşıcı Hastalıklar

Dergi:

Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi Vol.11 Issue 1, pp.30-35

Belge Tipi:

Makale

Yayın Tarihi:

3/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001314102

pISSN:

2147-9607